Oral

Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, July 26, 2023
AMN, Volunteering, Common stock, Male, Obesity, Histology, NASH, Diarrhea, Success, Half-life, Conference call, Internet, Triglyceride, Safety, Glucagon, Weight loss, Clinical trial, Pharmacokinetics, SAD, Balance sheet, X-ALD, Consultant, Disorder, DSM-IV codes, Trial of the century, Vomiting, Fibrosis, Plasma, Adrenoleukodystrophy, Magnetic resonance imaging, Hypoglycemia, Animal, Investment, Biopsy, SAN, Nausea, Webcast, Oral, GIP, MAD, Research, BMI, Therapy, GI, Human, Disease, Medical imaging, Pharmaceutical industry, Dietary supplement, Cryptocurrency, Vikings, Tmax, Patient, Conference

SAN DIEGO, July 26, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2023, and provided an update on its clinical pipeline and other corporate developments.

Key Points: 
  • Highlights from the Quarter Ended June 30, 2023, and Other Recent Events:
    "In the second quarter of 2023 Viking continued to build on the momentum achieved in the first quarter, following the successful Phase 1 results of the dual incretin receptor agonist VK2735 for obesity," stated Brian Lian, Ph.D., chief executive officer of Viking.
  • We ended the second quarter with approximately $393 million, placing us in a strong financial position, with runway to execute through multiple potential value-creating events."
  • During the second quarter, the company announced positive top-line results from its Phase 2b VOYAGE study evaluating VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis.
  • Management will host a conference call to discuss the company's second quarter financial results today at 4:30 pm Eastern.

Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit

Retrieved on: 
Wednesday, July 26, 2023
Operation, Interim, Retinal, Novel, NDA, Business, DR, Intravitreal injection, Diabetic retinopathy, MS, OCUP, Patient, Physician, Risk, Oral, FDA, SVP, Society, Treatment, Master of Engineering, ASRS, Pharmaceutical industry

FARMINGTON HILLS, Mich., July 26, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that results from the ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy will be presented at the American Society of Retinal Specialists (ASRS) annual scientific meeting to take place in Seattle, Washington, July 28 to August 1. In addition, Ronil Patel, MTech, MS, SVP of Operations & Business Development at Ocuphire, will provide a corporate update at the OIS Retina Innovation Summit on July 27, also in Seattle, Washington.

Key Points: 
  • In addition, Ronil Patel, MTech, MS, SVP of Operations & Business Development at Ocuphire, will provide a corporate update at the OIS Retina Innovation Summit on July 27, also in Seattle, Washington.
  • Ocuphire also announced that it has scheduled an End-of-Phase 2 meeting with the FDA in Q4 2023 to discuss the specifics of the APX3330 development program.
  • “Currently, patients with non-proliferative diabetic retinopathy (NPDR) are not treated due to the lack of non-invasive options on the market and the monthly time burden required for intravitreal injections.
  • Eighty percent of physicians prefer to use a wait-and-see approach for these patients rather than delivering a monthly biologic treatment where patients often become incomplete responders.

USOSM Salutes Dr. Clement Qaqish for Medical Mission Work

Retrieved on: 
Tuesday, July 25, 2023
Partnership, Surgeon, University, Education, Marketing, Birth, American Academy, Head, Rehabilitation, Plastic surgery, Cosmetic, Neck, History of the University of Maryland, College Park, American Board of Commissioners for Foreign Missions, Publication, Patient, DDS, Oral, Faculty, General surgery, Growth, Health, Oral and maxillofacial surgery, Dental, University of Western Ontario, Cleft lip and cleft palate, Dentistry, Nursing, MD

“We're excited to welcome Dr. Qaqish back from Africa," said USOSM President and CEO Richard Hall.

Key Points: 
  • “We're excited to welcome Dr. Qaqish back from Africa," said USOSM President and CEO Richard Hall.
  • “USOSM deeply appreciates the passion Dr. Qaqish has for helping those in need."
  • In addition, Dr. Qaqish has partnered with several other nonprofit organizations, such as Smile Train and Mercy Ships , for medical mission work.
  • Dr. Qaqish is the founder and medical director of San Diego Surgical Arts , a USOSM partner practice located in San Diego, California.

Imperative Care Announces Multiple Poster Presentations on the Zoom Stroke Solution at the Society of NeuroInterventional Surgery 20th Annual Meeting

Retrieved on: 
Thursday, July 20, 2023
Health, Medical Devices, Telemedicine, Virtual Medicine, Hospitals, Health Technology, General Health, Biotechnology, Stroke, Oral, Neuroradiology, Society, Annual general meeting, Pharmaceutical industry, Telescopic sight, Communications satellite

Imperative Care , a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced that new data from studies evaluating the Zoom Stroke Solution for the treatment of ischemic stroke will be presented at the Society of NeuroInterventional Surgery (SNIS) 2023 20th Annual Meeting taking place July 31-August 4 in San Diego, Calif.

Key Points: 
  • Imperative Care , a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced that new data from studies evaluating the Zoom Stroke Solution for the treatment of ischemic stroke will be presented at the Society of NeuroInterventional Surgery (SNIS) 2023 20th Annual Meeting taking place July 31-August 4 in San Diego, Calif.
  • The company also announced that there will be one late-breaking abstract presentation on the Zoom Stroke Solution at the meeting.
  • Poster presentations of the Zoom Stroke Solution at SNIS include:
    *All oral posters will be presented on Monday, July 31 between 4:00-5:00 p.m. P.T.
  • **Late-breaking abstract presentations will take place Wednesday, August 2 from 10:45 a.m.-12:00 p.m. PT in the San Diego Ballroom.

USOSM Launches Oral and Maxillofacial Surgery Centers of Excellence

Retrieved on: 
Tuesday, July 18, 2023
Communication, Partnership, Marketing, United States National Library of Medicine, Patient, Professional, Research, Certification, Interest, National library, Patient safety, DDS, Oral, Quality control, FACS, Ethics, Growth, Health, Oral and maxillofacial surgery, Dentistry, Nursing

Oral Surgery Management (USOSM) – a specialty management services company that exclusively serves premier oral and maxillofacial surgeons – is launching the USOSM Oral and Maxillofacial Surgery Centers of Excellence program.

Key Points: 
  • Oral Surgery Management (USOSM) – a specialty management services company that exclusively serves premier oral and maxillofacial surgeons – is launching the USOSM Oral and Maxillofacial Surgery Centers of Excellence program.
  • USOSM is the first company of its kind to launch a centers of excellence program of this caliber.
  • “We established that in the beginning by partnering exclusively with board-certified oral and maxillofacial surgeons, and we’ve continued that commitment to excellence through several quality enrichment programs.
  • The USOSM Oral and Maxillofacial Surgery Centers of Excellence program is our latest quality initiative.

China Precision Medicine Business Opportunities Databook 2023: Focus on Mepolizumab, Osimertinib, Aripiprazole Lauroxil, & Alectinib - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 13, 2023
Health, Pharmaceutical, Cloud, Molecule, SRL Diagnostics, Clinical Laboratory, Oncology, Biotechnology, Drug discovery, Health care, Personalized medicine, Bioinformatics, European Technology Platform Nanomedicine, CNS, Medication, Data wrangling, Ligation, Administration, Application, Nanopore sequencing, Ion semiconductor sequencing, Others, Update, Medicine, Route of administration, Oral, Injection (medicine), Therapy, Diagnosis, Infection, Semiconductor, Fine chemical, Marketing, Medical device, Pet industry

The "China Precision Medicine Business Opportunities Databook - Q2 2023 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Precision Medicine Business Opportunities Databook - Q2 2023 Update" report has been added to ResearchAndMarkets.com's offering.
  • China's precision medicine market size is expected to record a CAGR of 13% during 2023-2027 to reach US$6.403 billion by 2027, increasing from US$3.92 billion in 2023.
  • In-depth understanding of precision medicine market dynamics: Understand market opportunity, industry dynamics, key trends, and drivers across different market segments and sub-segments of the industry increate China.
  • 1 China Precision Medicine Market Size and Forecast, 2018-2027
    2 China Precision Medicine Market Share by Category, 2018-2027
    2.1 China Precision Medicine Market Size by Diagnosis, 2018-2027
    2.2 China Precision Medicine Market Size by Therapeutics, 2018-2027
    2.3 China Precision Medicine Market Size by Others, 2018-2027
    3 China Precision Medicine Market Share by Technology Platforms, 2018-2027
    3.1 Precision Medicine Market Size by Cloud-Based Platform, 2018-2027
    3.2 Precision Medicine Market Size by On-Premise Platform, 2018-2027
    4 China Precision Medicine Market Share by Technology, 2018-2027
    4.1 Precision Medicine Market Size by Bioinformatics, 2018-2027
    4.2 Precision Medicine Market Size by Big Data Analytics, 2018-2027
    4.3 Precision Medicine Market Size by Drug Discovery, 2018-2027
    4.4 Precision Medicine Market Size by Companion Diagnostics, 2018-2027
    4.5 Precision Medicine Market Size by Gene Sequencing, 2018-2027
    4.6 Precision Medicine Market Size by Others, 2018-2027
    5 China Precision Medicine Market Share by Gene Sequencing, 2018-2027
    5.1 Precision Medicine Market Size by Chain Termination Sequencing, 2018-2027
    5.2 Precision Medicine Market Size by Nanopore Sequencing, 2018-2027
    5.3 Precision Medicine Market Size by Sequencing by Ligation, 2018-2027
    5.4 Precision Medicine Market Size by Pyrosequencing, 2018-2027
    5.5 Precision Medicine Market Size by Ion Semiconductor Sequencing, 2018-2027
    5.6 Precision Medicine Market Size by Single Molecule Real Time Sequencing, 2018-2027
    5.7 Precision Medicine Market Size by Sequencing by Synthesis, 2018-2027
    6 China Precision Medicine Market Share by Drugs, 2018-2027
    6.1 Precision Medicine Market Size by Mepolizumab, 2018-2027
    6.2 Precision Medicine Market Size by Osimertinib, 2018-2027
    6.3 Precision Medicine Market Size by Aripiprazole Lauroxil, 2018-2027
    6.4 Precision Medicine Market Size by Alectinib, 2018-2027
    6.5 Precision Medicine Market Size by Others, 2018-2027
    7 China Precision Medicine Market Share by Route of Administration, 2018-2027
    7.1 Precision Medicine Market Size by Injectable, 2018-2027
    7.2 Precision Medicine Market Size by Oral, 2018-2027
    7.3 Precision Medicine Market Size by Others, 2018-2027
    8 China Precision Medicine Market Share by Application, 2018-2027
    8.1 Precision Medicine Market Size by Oncology, 2018-2027
    8.2 Precision Medicine Market Size by CNS, 2018-2027
    8.3 Precision Medicine Market Size by Cardiovascular, 2018-2027
    8.4 Precision Medicine Market Size by Infectious Diseases, 2018-2027
    8.5 Precision Medicine Market Size by Others, 2018-2027
    9 China Precision Medicine Market Share by End User, 2018-2027
    9.1 Precision Medicine Market Size by Pharmaceuticals and Biotechnology Companies, 2018-2027
    9.2 Precision Medicine Market Size by Diagnostics Companies, 2018-2027
    9.3 Precision Medicine Market Size by Healthcare IT Specialists/Big Data Companies, 2018-2027
    9.4 Precision Medicine Market Size by Clinical Laboratories, 2018-2027

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Positive Biomarker/Clinical Correlations from Phase 2 Biomarker Study at AAIC in Amsterdam

Retrieved on: 
Tuesday, July 11, 2023
Research, Other Health, General Health, Pharmaceutical, Biometrics, Mental Health, Clinical Trials, Science, Neurology, Biotechnology, FDA, Health, Other Science, Genotype, Atrophy, MH, Cerebral amyloid angiopathy, CAA, Prevalence, Pathology, NDA, Black box, COVID, Siderosis, Biomarker, MCI, Doctor of Philosophy, Female, Mild, Common, Blood, Plasma, MRI, Alzheimer's disease, ARIA, Occipital bone, Magnetic resonance imaging, Cortex, MD, Patient, Risk, Horseshoe kidney, CEST, Lateral ventricles, Composite, Medicine, Drug development, Oral, AD, Cerebral edema, MMSE, Conference, Neurotoxicity, Safety, Disease, Pharmaceutical industry, Medical imaging, APOE4, Alzheon, Early

ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of Early AD.

Key Points: 
  • ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of Early AD.
  • In mechanism-of-action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid (Aβ) oligomers at the Phase 3 clinical dose.
  • This population is the focus of Alzheon’s pivotal Phase 3 APOLLOE4 trial , which is now fully enrolled and will be completed in the third quarter of 2024.
  • We look forward to communicating the final 24-month data from our Phase 2 study later in 2023.”

Kansas City University Opens College of Dental Medicine to Address Oral Health Crisis

Retrieved on: 
Tuesday, June 27, 2023
Linda, Faculty, Learning, Workforce, HRSA, Health Resources and Services Administration, Osteopathic medicine in the United States, College, Student, Diabetes, Education, Dental education throughout the world, Dentistry, MPP, Native, Curriculum, COVID-19, Cardiovascular disease, Wiro Niessen, Science, Dental hygienist, Public expenditure, Radius, DO, Dentist, Alzheimer's disease, CDM, Patient, Kansas City University, Columbia University College of Dental Medicine, Dental care, Virtual reality, Oral, Harry, Bacteria, KCU, Health, MPH, Virus, Dental public health, University of New England College of Osteopathic Medicine, DMD

"We know poor oral health leads to poor overall health," said Marc B. Hahn, DO, president and CEO of KCU.

Key Points: 
  • "We know poor oral health leads to poor overall health," said Marc B. Hahn, DO, president and CEO of KCU.
  • Integrating dental medicine coursework with KCU's College of Osteopathic Medicine will lead future dentists to recognize how oral health problems can impact a patient's overall health, as well as promote interprofessional education in both colleges.
  • "The KCU College of Dental Medicine will integrate dental and medical education so that our students will be treating the whole patient," Linda Niessen, DMD, MPH, MPP founding dean of the College of Dental Medicine.
  • "We envision that the KCU College of Dental Medicine will become a center of excellence in the region improving oral health and increasing access to needed oral health care."

Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association’s Annual Conference

Retrieved on: 
Tuesday, June 27, 2023
Injection, Interim, American Diabetes Association, Diabetes, Safety, DR, Diabetic retinopathy, Paratriathlon, OCUP, HIV disease progression rates, Patient, Physician, Risk, Oral, American Association of Clinical Endocrinologists, FDA, ADA, Pharmaceutical industry, DRSS

at the 83 rd Scientific Sessions of the American Diabetes Association (ADA) in San Diego, CA on Saturday, June 24, 2023.

Key Points: 
  • at the 83 rd Scientific Sessions of the American Diabetes Association (ADA) in San Diego, CA on Saturday, June 24, 2023.
  • “We were pleased to present our ZETA-1 data on oral APX3330 at the world’s largest diabetes meeting that features important diabetic advances,” said Rick Rodgers, Interim Chief Executive Officer.
  • Prevention of progression is an important and clinically meaningful aspect of diabetes care for physicians, patients and payors.
  • APX3330 did not meet the primary endpoint (% of patients with a ≥ 2-step improvement in DRSS at week 24 in the study eye).

Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar

Retrieved on: 
Wednesday, June 21, 2023
ENDO, Roy J. and Lucille A. Carver College of Medicine, Senior, Serum, Pediatric endocrinology, SDS, DRS, MD, Division, Update, Transgender hormone therapy, LUMO, Database, University, Mother, University of Iowa Hospitals and Clinics, Albany Medical Center, Lumos, Growth, Hospital, NIH, Abstract, Endocrinology, Aes, University of Chile, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Șaeș, Public key certificate, Endocrine Society, Research, KOL, Saint Andrew's Society, University of Iowa, Oral, Diabetes, AHV, Pharmaceutical industry, Nursing, Dietary supplement, Child, Pediatrics

AUSTIN, Texas, June 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, is hosting today a virtual Key Opinion Leader (KOL) Webinar where Drs. Fernando Cassorla and Michael Tansey will highlight the encouraging new data and analysis on oral LUM-201 for idiopathic PGHD from the Phase 2 PK/PD OraGrowtH212 and dose-finding OraGrowtH210 Trials presented at the Endocrine Society (ENDO) Annual Meeting, held in Chicago, Illinois, June 15-18, 2023.

Key Points: 
  • Fernando Cassorla and Michael Tansey will highlight the encouraging new data and analysis on oral LUM-201 for idiopathic PGHD from the Phase 2 PK/PD OraGrowtH212 and dose-finding OraGrowtH210 Trials presented at the Endocrine Society (ENDO) Annual Meeting, held in Chicago, Illinois, June 15-18, 2023.
  • Cassorla and Tansey will be available to answer questions following their formal presentations.
  • To register for the virtual KOL Event, please click through the link HERE .
  • Cassorla and Tansey gave two oral presentations in the Update on Growth Disorders session at the 2023 ENDO Meeting.